0 false false false false false false false false false false true false false false false false false No description of principal activity 2023-02-21 Sage Accounts Production Advanced 2023 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP 14678399 2023-02-21 2024-06-30 14678399 2024-06-30 14678399 2023-02-20 14678399 bus:Director1 2023-02-21 2024-06-30 14678399 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-06-30 14678399 core:PatentsTrademarksLicencesConcessionsSimilar 2024-06-30 14678399 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-02-21 2024-06-30 14678399 core:PatentsTrademarksLicencesConcessionsSimilar 2023-02-21 2024-06-30 14678399 core:WithinOneYear 2024-06-30 14678399 core:ShareCapital 2024-06-30 14678399 core:RetainedEarningsAccumulatedLosses 2024-06-30 14678399 bus:SmallEntities 2023-02-21 2024-06-30 14678399 bus:AuditExempt-NoAccountantsReport 2023-02-21 2024-06-30 14678399 bus:SmallCompaniesRegimeForAccounts 2023-02-21 2024-06-30 14678399 bus:PrivateLimitedCompanyLtd 2023-02-21 2024-06-30 14678399 bus:FullAccounts 2023-02-21 2024-06-30
COMPANY REGISTRATION NUMBER: 14678399
Dose Labs Ltd
Filleted Unaudited Financial Statements
30 June 2024
Dose Labs Ltd
Statement of Financial Position
30 June 2024
30 Jun 24
Note
£
Fixed assets
Intangible assets
4
124,817
Current assets
Stocks
33,708
Debtors
5
16,901
Cash at bank and in hand
8,605
--------
59,214
Creditors: amounts falling due within one year
6
313,210
---------
Net current liabilities
253,996
---------
Total assets less current liabilities
( 129,179)
---------
Net liabilities
( 129,179)
---------
Capital and reserves
Called up share capital
1
Profit and loss account
( 129,180)
---------
Shareholders deficit
( 129,179)
---------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
For the period ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476 ;
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
Dose Labs Ltd
Statement of Financial Position (continued)
30 June 2024
These financial statements were approved by the board of directors and authorised for issue on 30 September 2024 , and are signed on behalf of the board by:
Mr J Bagley
Director
Company registration number: 14678399
Dose Labs Ltd
Notes to the Financial Statements
Period from 21 February 2023 to 30 June 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 5 Flanders Rd, London, W4 1NQ, United Kingdom.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods supplied, stated net of discounts and of Value Added Tax.
Intangible assets
Intangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated amortisation and impairment losses. Any intangible assets carried at revalued amounts, are recorded at the fair value at the date of revaluation, as determined by reference to an active market, less any subsequent accumulated amortisation and subsequent accumulated impairment losses. Intangible assets acquired as part of a business combination are only recognised separately from goodwill when they arise from contractual or other legal rights, are separable, the expected future economic benefits are probable and the cost or value can be measured reliably.
Amortisation
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:
Development costs
-
3 years
Patents, trademarks and licences
-
3 years
If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stock to its present location and condition.
Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Intangible assets
Development costs
Patents, trademarks and licences
Total
£
£
£
Cost
Additions
175,920
11,305
187,225
---------
--------
---------
At 30 June 2024
175,920
11,305
187,225
---------
--------
---------
Amortisation
Charge for the period
58,640
3,768
62,408
---------
--------
---------
At 30 June 2024
58,640
3,768
62,408
---------
--------
---------
Carrying amount
At 30 June 2024
117,280
7,537
124,817
---------
--------
---------
5. Debtors
30 Jun 24
£
Trade debtors
4,487
Other debtors
12,414
--------
16,901
--------
6. Creditors: amounts falling due within one year
30 Jun 24
£
Trade creditors
26,710
Other creditors
286,500
---------
313,210
---------